ALK B ALK-ABELLO A/S

ALK upgrades its full-year revenue outlook

ALK upgrades its full-year revenue outlook

Inside information

ALK (ALKB:DC / OMX: ALK B) today announced that the 2025 full-year financial outlook has been upgraded.

  • Revenue is now expected to grow by 12-14% in local currencies (previously 9-13% growth).
  • The operating profit (EBIT) margin is still expected to improve by 5 percentage points to 25%.

The updated outlook reflects higher-than-expected revenue in Europe in Q2 and an improved outlook for the rest of the year. Q2 was positively influenced by sales of adrenaline autoinjectors and by the momentum for tablets in Europe which is expected to continue in the second half of the year. This momentum is expected to be supported by solid growth in sales of tablets in North America. Moreover, the updated forecast reflects reduced risks associated with market conditions in Europe for the rest of the year. On the basis of the improved revenue outlook, ALK has decided to allocate additional funds to strategic growth investments in the second half-year.

According to preliminary financial results for Q2, total revenue grew by 12% in local currencies to DKK 1,527 million (1,374), while EBIT increased by 41% in local currencies to DKK 375 million (264), equivalent to an EBIT margin of 25%.

ALK will publish its Q2 report on 21 August 2025. A presentation for analysts and investors will take place on the same day at 13.30 CEST.

ALK-Abelló A/S

For further information please contact:

Investor Relations: Per Plotnikof, tel. , mobile

Media: Maiken Riise Andersen, tel.

This information is information that ALK is obliged to make public pursuant to the EU Market Abuse Regulation.

About ALK

ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,800 people worldwide and is listed on Nasdaq Copenhagen. Find more information at  

Attachment



EN
12/08/2025

Underlying

ALK BALK-ABELLO A/S

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ALK-ABELLO A/S

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
08/22/25 August 22, 2025 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

Six-month interim report (Q2) 2025 (unaudited) - English version only

Six-month interim report (Q2) 2025 (unaudited) - English version only Bemærk venligst, at rapporten udelukkende forefindes på engelsk. ALK delivers 12% organic revenue growth with operating profit up 41% in Q2 Q2 results exceeded expectations, driven by an improved momentum for tablets and adrenaline autoinjectors. Sales in Europe were ahead of plan, supporting 12% overall revenue growth, despite phasing of product shipments to International markets. The operating profit (EBIT) increased by 41%, and the full-year revenue outlook has been upgraded.    Q2 performance highlights Comp...

August 21, 2025 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

Six-month interim report (Q2) 2025 (unaudited)

Six-month interim report (Q2) 2025 (unaudited) ALK delivers 12% organic revenue growth with operating profit up 41% in Q2 Q2 results exceeded expectations, driven by an improved momentum for tablets and adrenaline autoinjectors. Sales in Europe were ahead of plan, supporting 12% overall revenue growth, despite phasing of product shipments to International markets. The operating profit (EBIT) increased by 41%, and the full-year revenue outlook has been upgraded.    Q2 performance highlights Comparative figures for Q2 2024 are shown in brackets. Growth rates are stated in local currencies...

August 21, 2025 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

Invitation til præsentation af ALK’s regnskab for første halvår (Q2) 2...

Invitation til præsentation af ALK’s regnskab for første halvår (Q2) 2025 torsdag den 21. august 2025 ALK (ALKB.DC / OMX: ALK B) offentliggør delårsrapport for første halvår (Q2) af 2025 om morgenen torsdag den 21. august 2025. ALK afholder senere samme dag kl. 13.30 en præsentation for investorer og analytikere, hvor ledelsen kommenterer på resultat og forventninger samt besvarer spørgsmål. ALK vil være repræsenteret ved Peter Halling, Adm. direktør, Claus Steensen Sølje, Finansdirektør og Per Plotnikof, IR-chef.  Live audio-webcast Mødet audiocastes live på , hvor genafspilning af pr...

August 14, 2025 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

Invitation to the presentation of ALK’s first six months (Q2) 2025 res...

Invitation to the presentation of ALK’s first six months (Q2) 2025 results on Thursday, 21 August 2025 ALK (ALKB.DC / OMX: ALK B) will publish its results for the first six months of 2025 in the morning on Thursday, 21 August 2025. Later on the same day, the company will host a presentation for investors and analysts at 1:30 p.m. CEST, where ALK’s management will comment on the results for the first six months and the outlook and be available for questions. ALK will be represented by Peter Halling, President & CEO, Claus Steensen Sølje, CFO and Per Plotnikof, VP, Head of IR.  Live aud...

August 14, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch